This review summarizes the impact of systemic and ocular inflammatory disorders on
diabetes mellitus (DM) and
diabetic retinopathy (DR). Local
inflammation is a key pathology in
diabetic retinopathy (DR) and is also an evolving target for clinical
therapy. The legacy effects of local
inflammation at the intracellular level make DR a persistent self-driven vicious process. Ocular
inflammation is accompanied as well as incited by systemic
inflammation due to
diabetes mellitus (DM) itself. Over the years, a multitude of studies have evaluated the impact of systemic inflammatory disorders (
SIDs, like
rheumatoid arthritis, lupus,
psoriasis, etc.) and anti-inflammatory drugs prescribed for managing them on manifestations of DM. Recent studies have indicated increased
insulin resistance to be a result of chronic
inflammation, and the anti-inflammatory drugs to have a protective effect towards DM. Very few studies have evaluated the impact of
SIDs on DR. Furthermore, the evidence from these studies is conflicting, and while local anti-inflammatory
therapy has shown a lot of clinical potential for use in DR, the results of systemic anti-inflammatory
therapies have been inconsistent. The impact of local ocular
inflammation due to
uveitis on DR is a crucial aspect that has not been evaluated well at present. Initial pre-clinical studies and small-sized clinical reports have shown a strong and positive relationship between the presence of
uveitis and the severity of DR as well as its progression, while larger cross-sectional patient surveys have refuted the same. The long term impact of ocular
inflammation due to
uveitis on DR needs to be studied while adjusting for confounders.